Applikon Biotechnology starts construction of new facility in Delft

The building will accommodate 100 people and be completed next summer

Applikon Biotechnology, a private Dutch manufacturer of bioreactor systems for research and production use headquartered in Schiedam, has started the construction of a new facility on the Technopolis high-tech science park in Delft so that it can tap into international biopharmaceutical markets.

The 3,700m2 building will include offices, laboratories, a workshop and warehouse and accommodate approximately 100 people. It is scheduled for completion next summer.

Erik Kakes, Applikon Biotechnology’s international sales and marketing director said: ‘The investment in the new building is a clear signal that we have confidence in our market, our organisation and our motivated and well-trained staff.

‘A number of large customers, including Delft University and DSM, are moving to Technopolis and from this new location we will be able to further improve our service to our customers.’

Applikon Biotechnology is a global leader in the field of laboratory bioreactor systems and has subsidiaries in the US, England and China.

Companies